News & Events

“Lentiviral-driven directed evolution of G protein-coupled receptors (GPCRs) and anti-GPCR antibodies”.

Neuroscience & Non-Communicable Diseases Seminar Series

Speaker: Associate Professor Daniel Scott, Florey Institute of Neuroscience and Mental Health. 


A/Prof. Daniel Scott completed his PhD at The University of Melbourne in 2007, during which he characterised the molecular pharmacology of the relaxin receptor, RXFP1. In 2008 he was awarded an NHMRC CJ Martin Fellowship, allowing him to work as a postdoctoral researcher in the laboratory of Prof. Andreas Plückthun in Zurich, Switzerland. While in Zurich he invented a novel method, called CHESS, which enabled the rapid engineering of stabilized membrane proteins through directed evolution for structural biology and drug discovery. The CHESS technology was spun out into a Swiss biotechnology company, called G7 therapeutics, co-founded by Daniel in 2013. In 2016 G7 therapeutics was acquired by Sosei Heptares, who continue to use CHESS for drug discovery. In November 2011, Daniel took up a group leader position at the Florey Institute of Neuroscience and Mental Health, and his laboratory now comprises 11 PhD students, three postdoctoral fellows and two Honours students. The Scott laboratory is focused on using protein engineering methods, including rational design and directed evolution, to facilitate study of the molecular mechanisms underpinning G protein-coupled receptor (GPCR) function and drug discovery. Daniel has published 50 research articles, is an inventor on three GPCR-related patents (all granted in various jurisdictions, one licensed) and is passionate about training the next generation of scientists (having supervised 12 PhDs and 16 Hons/MSc students to completion).

Enquiries: Lindsay Wu  

Event Date: 
Friday, 26 November 2021 - 3:00pm
Online via Microsoft Teams Meeting
Event Type: 
Booking deadline: